Author

M. Mezes

Observed name: Maria Mezes

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Yale University, Bristol-Myers Squibb (United States), PhytoCeutica (United States)

OpenAlex ID: A5000980500

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies

2010 · M. Wasif Saif, F. Lansigan, et al. · Phytomedicine · 92

A phase I/II study of PHY906 plus capecitabine (CAP) in patients (pts) with advanced pancreatic cancer (APC)

2008 · C. J. Hoimes, L. Lamb, et al. · Journal of Clinical Oncology · 11

A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC)

2009 · M. W. Saif, J. Li, et al. · Journal of Clinical Oncology · 8

A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.

2013 · Alexander M. Lesokhin, Martin Gutierrez, et al. · Journal of Clinical Oncology · 2

Works count: 4

Citation count: 113

H-index: 3

I10-index: 2